A simple assay system for examination of the inhibitory potential in vivo of decoy RNAs, ribozymes and other drugs by measuring the Tat-mediated transcription of a fusion gene composed of the long terminal repeat of HIV-1 and a gene for luciferase

Journal of Controlled Release

Volumn 53, Issue 1-3, 1998, Pages 159-173

  Koseki, Shiori ^a,c   Ohkawa, Jun ^a,c   Yamamoto, Rika ^a,c   Takebe, Yutaka ^b   Taira, Kazunari ^a,c  

^a Ministry of International Trade and Industry   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Decoy; HIV 1; Inhibition; Luciferase; Ribozyme

Indexed keywords

COMPLEMENTARY DNA; COMPLEMENTARY RNA; PLASMID VECTOR; RIBOZYME;

CONFERENCE PAPER; DRUG DESIGN; DRUG MECHANISM; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENE FUSION; GENE REPRESSION; GENE STRUCTURE; GENE THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; NONHUMAN; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

ARTIFICIAL GENE FUSION; BASE SEQUENCE; GENE PRODUCTS, TAT; HELA CELLS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; LUCIFERASES; NUCLEIC ACID CONFORMATION; PLASMIDS; RNA; RNA, CATALYTIC; TRANSCRIPTION, GENETIC;

EID: 0032580454     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(97)00250-2     Document Type: Conference Paper

References (72)

1. J.A.H. Murray (Ed.), Antisense RNA and DNA, Wiley-Liss, New York, 1992.
2. R.P. Erickson, J.G. Izant (Eds.), Gene Regulation: Biology of Antisense RNA and DNA, Raven Press, New York, 1992.
3. F. Eckstein, D.M.J. Lilley (Eds.), Nucleic Acids and Molecular Biology, Vol. 10, Catalytic RNA, Springer, Heidelberg, 1996.
4. Birikh K.R., Heaton P.A., Eckstein F. The structure, function and application of the hammerhead ribozyme. Eur. J. Biochem. 245:1997;1-16.
5. Altman S. Ribonuclease P. J. Biol. Chem. 265:1990;20053-20056.
6. Cech T.R. Self-splicing of group I introns. Ann. Rev. Biochem. 59:1990;543-568.
7. Symons R.H. Small catalytic RNAs. Ann. Rev. Biochem. 61:1992;641-671.
8. Uhlenbeck O.C. A small catalytic oligoribonucleotide. Nature. 328:1987;596-600.
9. Haseloff J., Gerlach W.L. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature. 334:1988;585-591.
10. Piccirilli J.A., Vyle J.S., Caruthers M.H., Cech T.R. Metal ion catalysis in the Tetrahymena ribozyme reaction. Nature. 361:1993;85-88.
11. Yarus M. How many catalytic RNAs? Ions and the Cheshire cat conjecture. FASEB J. 7:1993;31-39.
12. 2+ ions in ribozyme reactions. FASEB J. 7:1993;137-142.
13. Steitz T.A., Steitz J.A. A general two-metal-ion mechanism for catalytic RNA. Proc. Natl. Acad. Sci. USA. 90:1993;6498-6502.
14. Pyle A.M. Ribozymes: a distinct class of metalloenzymes. Science. 261:1993;709-714.
15. Dahm S.C., Derrick W.B., Uhlenbeck O.C. Evidence for the role of solvated metal hydroxide in the hammerhead cleavage mechanism. Biochemistry. 32:1993;13040-13045.
16. Uebayasi M., Uchimaru T., Koguma T., Sawata S., Shimayama T., Taira K. Theoretical and experimental considerations on the hammerhead ribozyme reactions: divalent magnesium ion-mediated cleavage of phosphorus-oxygen bonds. J. Org. Chem. 59:1994;7414-7420.
17. Sawata S., Komiyama M., Taira K. Kinetic evidence based on solvent isotope effects for the nonexistence of a proton-transfer process in reactions catalyzed by a hammerhead ribozyme: implication to the double-metal-ion mechanism of catalysis. J. Am. Chem. Soc. 117:1995;2357-2358.
18. P.K.R. Kumar, D.-M. Zhou, K. Yoshinari, K. Taira, Mechanistic studies on hammerhead ribozymes, in: F. Eckstein, D.M.J. Lilley (Eds.), Nucleic Acids and Molecular Biology, Vol. 10, Catalytic RNA, Springer, Heidelberg, 1996, pp. 217-230.
19. Zhou D.-M., Usman N., Wincott F.E., Matulic-Adamic J., Orita M., Zhang L.-H., Komiyama M., Kumar P.K.R., Taira K. Evidence for the rate-limiting departure of the 5′-oxygen in nonenzymatic and hammerhead ribozyme-catalyzed reactions. J. Am. Chem. Soc. 118:1996;5862-5866.
20. 2+ ion with the pro-R oxygen of the scissile phosphate in the transition state of a hammerhead ribozyme-catalyzed reaction. J. Am. Chem. Soc. 118:1996;8969-8970.
21. Bassi G.S., Mollegaard N.E., Murchie A.I.H., von Kitzing E., Lilley D.M.J. Ionic interactions and the global conformations of the hammerhead ribozyme. Nat. Struct. Biol. 2:1995;45-55.
22. Orita M., Vinayak R., Andrus A., Warashina M., Chiba A., Kamiwa H., Nishikawa F., Nishikawa S., Taira K. Magnesium-mediated conversion of an inactive form of a hammerhead ribozyme to an active complex with its substrate: an investigation by NMR spectroscopy. J. Biol. Chem. 271:1996;9447-9454.
23. Pley H.W., Flaherty K.M., McKay D.B. Three-dimensional structure of a hammerhead ribozyme. Nature. 372:1994;68-74.
24. Scott W.G., Finch J.T., Klug A. The crystal structure of an all-RNA hammerhead ribozyme: a proposed mechanism for RNA catalytic cleavage. Cell. 81:1995;991-1002.
25. Scott W.G., Klug A. Ribozymes: structure and mechanism in RNA catalysis. Trends Biochem. Sci. 21:1996;220-224.
26. Scott W.G., Klug A. Capturing the structure of a catalytic RNA intermediate: the hammerhead ribozyme. Science. 274:1996;2065-2069.
27. Goodchild J., Kohli V. Ribozymes that cleave an RNA sequence from human immunodeficiency virus: the effect of flanking sequence on rate. Arch. Biochem. Biophys. 284:1991;386-391.
28. McCall M.J., Hendry P., Jennings P.A. Minimal sequence requirements for ribozyme activity. Proc. Natl. Acad. Sci. USA. 89:1992;5710-5714.
29. Tuschl T., Eckstein F. Hammerhead ribozymes: importance of stem-loop II for activity. Proc. Natl. Acad. Sci. USA. 90:1993;6991-6994.
30. Thomson J.B., Tuschl T., Eckstein F. Activity of hammerhead ribozymes containing non-nucleotidic linkers. Nucleic Acids Res. 21:1993;5600-5603.
31. Fu D.J., Benseler F., McLaughlin L.W. Hammerhead ribozymes containing non-nucleoside linkers are active RNA catalysts. J. Am. Chem. Soc. 116:1994;4591-4598.
32. M Long D., Uhlenbeck O.C. Kinetic characterization of intramolecular and intermolecular hammerhead RNAs with stem II deletions. Proc. Natl. Acad. Sci. USA. 91:1994;6977-6981.
33. Amontov S.V., Taira K. Hammerhead minizymes with high cleavage activities: a dimeric structure as the active conformation of minizymes. J. Am. Chem. Soc. 118:1996;1624-1628.
34. 2+ ions of the activities of dimeric hammerhead minizymes. FEBS Lett. 386:1996;99-102.
35. Sugiyama H., Hatano K., Saito I., Amontov S., Taira K. Catalytic activities of hammerhead ribozymes with a triterpenoid linker instead of stem/loop II. FEBS Lett. 392:1996;215-219.
36. Kuwabara T., Amontov S., Warashina M., Ohkawa J., Taira K. Characterization of several kinds of dimer minizyme: simultaneous cleavage at two sites in HIV-1 tat mRNA by dimer minizymes. Nucleic Acids Res. 24:1996;2302-2310.
37. Bratty J., Chartrand P., Ferbeyre G., Cedergren R. The hammerhead RNA domain, a model ribozyme. Biochim. Biophys. Acta. 1216:1993;345-359.
38. Dahm S.A., Uhlenbeck O.C. Role of divalent metal ions in the hammerhead RNA cleavage reaction. Biochemistry. 30:1991;9464-9469.
39. 2+ binding. Biochemistry. 30:1991;5145-5150.
40. Slim G., Gait M.J. Configurationally defined phosphorothioate-containing oligoribonucleotides in the study of the mechanism of cleavage of hammerhead ribozymes. Nucleic Acids Res. 19:1991;1183-1188.
41. Fujita S., Koguma T., Ohkawa J., Mori K., Kohda T., Kise H., Nishikawa S., Iwakura M., Taira K. Discrimination of a single base change in a ribozyme using the gene for dihydrofolate reductase as a selective marker in Escherichia coli. Proc. Natl. Acad. Sci. USA. 94:1997;391-396.
42. Kawasaki H., Ohkawa J., Tanishige N., Yoshinari K., Murata T., Yokoyama K.K., Taira K. Selection of the best target site for ribozyme-mediated cleavage within a fusion gene for adenovirus E1A-associated 300 kDa protein (p300) and luciferase. Nucleic Acids Res. 24:1996;3010-3016.
43. Sarver N., Cantin E.M., Chang P.S., Zaia J.A., Ladne P.A., Stephens D.A., Rossi J.J. Ribozymes as potential anti-HIV-1 therapeutic agents. Science. 247:1990;1222-1225.
44. Altman S. RNA enzyme directed gene therapy. Proc. Natl. Acad. Sci. USA. 90:1993;10898-10900.
45. Ohkawa J., Yuyama N., Takebe Y., Nishikawa S., Taira K. Importance of independence in ribozyme reactions: kinetic behavior of trimmed and of simply connected multiple ribozymes with potential activity against human immunodeficiency virus. Proc. Natl. Acad. Sci. USA. 90:1993;11302-11306.
46. Sullenger B., Gallardo H., Ungers G., Gilboa E. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell. 63:1990;601-608.
47. Lisziewicz J., Rappaport J., Dhar R. Tat-regulated production of multimerized TAR RNA inhibits HIV-1. New Biol. 3:1991;82-89.
48. Lee S.W., Gallardo H.F., Gaspar O., Smith C., Gilboa E. Inhibition of HIV-1 in CEM cells by a potent TAR decoy. Gene Ther. 2:1995;377-384.
49. Gaynor R. Cellular transcription factors involved in the regulation of HIV-1 gene expression. AIDS. 6:1992;347-363.
50. Rosen C.A., Sodroski J.G., Heseltine W.A. The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat. Cell. 41:1985;813-823.
51. Dayton A.I., Sodroski J.G., Rosen C.A., Goh W.C., Haseltine W.A. The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell. 44:1986;941-947.
52. Fisher A.G., Feinberg M.B., Josephs S.F., Harper M.E., Marselle L.M., Reyes G., Gonda M.A., Aldovini A., Debouk C., Gallo R.C., Wong-Staal F. The trans-activator gene of HTLV-III is essential for virus replication. Nature. 320:1986;367-371.
53. Feng S., Holland E.C. HIV-1 tat trans-activation requires the loop sequence within tar. Nature. 334:1988;165-167.
54. Jakobovits A., Smith D.H., Jakobovits E.B., Capon D.J. A discrete element 3′ of human immunodeficiency virus 1 (HIV-1) and HIV-2 mRNA initiation sites mediates transcriptional activation by an HIV trans activator. Mol. Cell. Biol. 8:1988;2555-2561.
55. Berkhout B., Silverman R.H., Jeang K.T. Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell. 59:1989;273-282.
56. Cullen B.R. Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism. Cell. 46:1986;973-982.
57. Peterlin B.M., Luciw P.A., Barr P.J., Walker M.D. Elevated levels of mRNA can account for the transactivation of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA. 83:1986;9734-9738.
58. Rice A.P., Mathews M.B. Transcriptional but not translational regulation of HIV-1 by the tat gene product. Nature. 332:1988;551-553.
59. Berkhout B., Jeang K.T. Trans activation of human immunodeficiency virus type 1 is sequence specific for both the single-stranded bulge and loop of the trans-acting-responsive hairpin: a quantitative analysis. J. Virol. 63:1989;5501-5504.
60. Dingwell C., Ernberg I., Gait M.J., Green S.M., Heaphy S., Karn J., Lowe A.D., Singh M., Skinner M.A., Valerio R. Human immunodeficiency virus I tat protein binds trans-activation responsive region (TAR) RNA in vitro. Proc. Natl. Acad. Sci. USA. 86:1989;6925-6929.
61. Cordingley M.G., La Femina R.L., Callahan P.L., Condra J.H., Sardana V.V., Graham D.J., Nguyen T.M., Le Grow K., Gotlib L., Schlabach A.J., Colonno R.J. Sequence-specific interaction of Tat protein and Tat peptides with the transactivation-response sequence element of human immunodeficiency virus type 1 in vitro. Proc. Natl. Acad. Sci. USA. 87:1990;8985-8989.
62. Roy S., Delling U., Chen C.-H., Rosen C.A., Sonenberg N. A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation. Genes Dev. 4:1990;1365-1373.
63. Weeks K.M., Ampe C., Schultz S.C., Steitz T.A., Crothers D.M. Fragments of the HIV-1 Tat protein specifically bind TAR RNA. Science. 249:1990;1281-1285.
64. Weeks K.M., Crothers D.M. RNA recognition by Tat-derived peptides: interaction in the major groove? Cell. 66:1991;577-588.
65. Churcher M.J., Lamont C., Hamy F., Dingwell C., Green S.M., Lowe A.D., Bulter P.D.G., Gait M.J., Karn J. High affinity binding of TAR RNA by the human immunodeficiency virus type-1 tat protein requires base-pairs in the RNA stem and amino acid residues flanking the basic region. J. Mol. Biol. 230:1993;90-110.
66. Ensoli B., Barillari G., Salahuddin S.Z., Gallo R.C., Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature. 345:1990;84-86.
67. Ensoli B., Buonaguro L., Barillari G., Fiorelli V., Gendelman R., Morgan R.A., Wingfield P., Gallo R.C. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J. Virol. 67:1993;277-287.
68. Yamamoto R., Koseki S., Ohkawa J., Murakami K., Nishikawa S., Taira K., Kumar P.K.R. Inhibition of transcription by TAR RNA in nuclear extracts of HeLa cells. Nucleic Acids Res. 25:1997;3445-3450.
69. Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., Martin M.A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:1986;284-291.
70. Zuker M., Stiegler P. Optimal computer folding of large RNA sequences using thermodynamics and auxiliary information. Nucleic Acids Res. 9:1981;133-148.
71. Alam J., Cook L.J. Reporter genes: application to the study of mammalian cells. Anal. Biochem. 188:1990;245-254.
72. Takebe Y., Seiki M., Fujisawa J., Hoy P., Yokota K., Arai K., Yoshida M., Arai N. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol. Cell. Biol. 8:1988;466-472.